Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy [PDF]
Pharmacology Research and Perspectives, 2019 Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half‐life allowing once ...
Voon Ong
exaly +4 more sources
Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique ...
David Perlin +2 more
exaly +5 more sources
Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Guillermo Garcia-Effron +1 more
exaly +6 more sources
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Microbiology Spectrum, 2023 Rezafungin is a novel once-weekly echinocandin for intravenous injection currently in development for the treatment of Candida infections and the prevention of Candida, Aspergillus, and Pneumocystis infections in allogeneic blood and marrow transplant ...
Voon Ong, Taylor Sandison
exaly +5 more sources
Efficacy of rezafungin in a case of Candida spondylodiskitis [PDF]
Journal of Bone and Joint InfectionRezafungin, which only requires weekly administration, is a potential candidate for difficult-to-treat infections that require long-term antimicrobial treatment, such as bone and joint infections.
M. Lahouati +9 more
doaj +5 more sources
Infectious Diseases and TherapyRezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream.
Ryan Dare +2 more
exaly +2 more sources
Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model
Pathogens and ImmunityBackground: Endophthalmitis, a severe infection of the intraocular tissues that can result in permanent loss of vision if not immediately treated, is often caused by fungi, namely Candida albicans.
John Saghir +5 more
doaj +3 more sources
A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin
IDCasesAntifungal resistance in Candida glabrata can develop to different classes of drugs, including the azoles and echinocandins. This organism is known to cause infective endocarditis with a particular predilection for prosthetic valves.
Divya Chandramohan +5 more
doaj +3 more sources
Rezafungin in special populations with candidaemia and/or invasive candidiasis
Journal of InfectionAchieving and maintaining therapeutic drug exposures with antifungals can be challenging in special patient populations, such as those with organ dysfunction (liver or kidney) or obesity, or elderly patients, due to dose-exposure relationships and potential drug-drug interactions.
George Thompson +2 more
exaly +3 more sources
Clinical and Translational ScienceThe risk of clinically relevant drug–drug interactions (DDIs) for therapeutic peptides remains unclear, mandating a comprehensive analysis for this modality.
Carolina Säll +6 more
doaj +2 more sources